News for Evolus, Inc. (0K16.L)

Revenue (Q4 2024): $79 million, a 30% increase over Q4 2023.Full Year Revenue (2024): $266.3 million, a 32% increase over 2023.US Product Revenue: Approximatel

Mar 04, 2025 / 09:30PM GMTOperator Good afternoon, everyone, and thank you for standing by. Welcome to Evolus fourth quarter in full year 2024 earnings conferen

The following slide deck was published by Evolus, Inc.

Evolus, Inc. (NASDAQ:EOLS) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ETCompany ParticipantsNareg Sagherian - VP and Head of Global IR and...

Significant Stock Acquisition by TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) On February 28, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed

Evolus (EOLS) delivered earnings and revenue surprises of -83.33% and 0.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

[url="]Evolus, Inc.[/url] (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results f

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Evolus, Inc.

On February 25, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a significant transaction by acquiring an additional 2,000,000 shares of Acelyrin

[url="]Evolus, Inc.[/url] (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its man

Overview of the Recent Transaction Stonepine Capital Management, LLC (Trades, Portfolio), a prominent investment firm, recently made a strategic move by acquiri

On February 18, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 5,298,328 shares of Acelyrin Inc. This acqu

[url="]Evolus, Inc.[/url] (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that

On February 7, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a significant transaction by acquiring 4,210,525 shares of Galapagos NV. This acqu

On December 31, 2024, GREAT POINT PARTNERS LLC (Trades, Portfolio) executed a notable transaction by acquiring 1,381,759 shares of Vistagen Therapeutics Inc at

On December 31, 2024, GREAT POINT PARTNERS LLC (Trades, Portfolio) executed a significant transaction involving Unicycive Therapeutics Inc (UNCY). The firm adde

On December 31, 2024, GREAT POINT PARTNERS LLC (Trades, Portfolio) executed a notable transaction by increasing its holdings in ProMIS Neurosciences Inc. The fi

On December 31, 2024, GREAT POINT PARTNERS LLC (Trades, Portfolio) executed a significant transaction by acquiring an additional 926,972 shares of Outlook Thera

On December 31, 2024, GREAT POINT PARTNERS LLC (Trades, Portfolio) made a strategic move by acquiring an additional 39,176 shares of OptiNose Inc at a price of